Jeffrey Graybill

Jeffrey Graybill joined Immatics in July 2025 and is responsible for the commercialization activities within the Chemistry, Manufacturing and Controls (CMC) department to support the launch of anzu-cel and portfolio cell therapy programs.

With over two decades of experience in CMC and Operations roles in biotechnology, Jeffrey plays a key role in developing patient-focused CMC strategies for the commercialization of late-stage cell therapy clinical programs. His career includes cross-functional program management and leadership roles across Amgen, Juno Therapeutics (BMS) and Cargo Therapeutics. He also played a key role in the launch and early lifecycle of Breyanzi, BMS’s first cell therapy, and looks forward to applying these experiences to future cell therapy products.

Jeffrey Graybill holds a bachelor’s degree in Biological Engineering from Louisiana State University and a master's degree in Bioscience from Keck Graduate Institute.